Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Accelerated and intensified manufacturing of an adenovirus-vectored vaccine to enable rapid outbreak response.

Joe CCD. et al, (2023), Biotechnol Bioeng

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration

DOUGLAS A. et al, (2023), NPJ Vaccines

Measurement of Adenovirus-Based Vector Heterogeneity.

Hickey JM. et al, (2023), J Pharm Sci, 112, 974 - 984

Rapid-response manufacturing of adenovirus-vectored vaccines

Joe CCD. et al, (2023), Nature Biotechnology

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.

Madhavan M. et al, (2022), EBioMedicine, 85

Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial.

Jenkin D. et al, (2022), Lancet Microbe, 3, e663 - e671

STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines.

Padron-Regalado E. et al, (2022), Sci Rep, 12

Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies.

Ng WM. et al, (2022), Cell Host Microbe

Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies

Ng W. et al, (2022)

Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.

Joe CCD. et al, (2022), Biotechnol Bioeng, 119, 48 - 58

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Clemens SAC. et al, (2021), Nature Communications, 12

Publisher Correction: Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.

Dulal P. et al, (2021), Sci Rep, 11

Stability of chimpanzee adenovirus vectored vaccines (Chadox1 and chadox2) in liquid and lyophilised formulations

Berg A. et al, (2021), Vaccines, 9

Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.

Dulal P. et al, (2021), Sci Rep, 11

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire.

Swanson PA. et al, (2021), Science translational medicine, eabj7211 - eabj7211

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.

Feng S. et al, (2021), Nat Med

T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire.

Swanson PA. et al, (2021)

Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination.

Minassian AM. et al, (2021), Med (New York, N.Y.), 2, 701 - 719.e19

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

Barrett JR. et al, (2021), Nature medicine

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Barrett JR. et al, (2021), Nature medicine

Load More

Include forthcoming?